Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

• The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)

  2026 Annals of the Rheumatic Diseases article Medicine Systemic Sclerosis and Related Diseases Open access

  5

  citations
• A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC score

  2025 Lara D. Veeken article Medicine Systemic Sclerosis and Related Diseases Open access

  8

  citations
• Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study

  2025 Lara D. Veeken article Medicine Systemic Sclerosis and Related Diseases Open access

  7

  citations
• Fibrosis: cross-organ biology and pathways to development of innovative drugs

  2025 Nature Reviews Drug Discovery review Medicine Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Open access

  97

  citations
• Quantitative 18F-FDG PET-CT can assess presence and extent of interstitial lung disease in early severe diffuse cutaneous systemic sclerosis

  2024 Arthritis Research & Therapy article Medicine Systemic Sclerosis and Related Diseases Open access

  12

  citations
• Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases

  2024 Immunological Reviews review Medicine Systemic Sclerosis and Related Diseases Open access

  7

  citations
• Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

  2023 Arthritis & Rheumatology article Medicine Systemic Sclerosis and Related Diseases Open access

  44

  citations
• Interstitial Lung Disease

  2023 Rheumatic Disease Clinics of North America article Medicine Systemic Sclerosis and Related Diseases Open access

  11

  citations
• A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

  2022 RMD Open review Medicine Rheumatoid Arthritis Research and Therapies Open access

  49

  citations
• Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

  2022 Annals of the Rheumatic Diseases article Medicine Rheumatoid Arthritis Research and Therapies Open access

  79

  citations
• Systemic sclerosis in the time of COVID-19

  2022 The Lancet Rheumatology article Medicine Systemic Sclerosis and Related Diseases Open access

  24

  citations
• Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison

  2022 Clinical and Experimental Rheumatology article Medicine Salivary Gland Disorders and Functions Open access

  11

  citations
• New risk model is able to identify patients with a low risk of progression in systemic sclerosis

  2021 RMD Open article Medicine Systemic Sclerosis and Related Diseases Open access

  10

  citations

13 results